DGAP-News

Aladdin Healthcare Technologies completes AI-driven Drug Discovery Platform (AIDD) for Commercial Use in Drug Development - Seite 2

Wade Menpes-Smith, CEO of Aladdin healthcare Technologies, comments: "Aladdin can now officially provide valuable solutions to the pharmaceutical industry via our proprietary AI Drug Discovery Platform that can accelerate the drug development process, covering the process of Virtual Screening, Hit to Lead and Lead Optimisation."

Aladdin is also working on several promising pipelines for the small molecule drug discovery in the early stage. Small molecule drugs are relatively simple chemical compounds. These compounds have a small molecular mass and their biggest advantage is the oral bioavailability. Already in May this year, Aladdin achieved two milestones in drug development against age-related diseases and COVID-19, by discovering new optimised compounds with its AIDD platform. The successful release of Aladdin's proprietary platform confirms again the capability of the Company to achieve groundbreaking milestones in the field of drug development. This opens the door to many relevant partnerships in the pharmaceutical industry.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.